ES2188743T3 - Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos. - Google Patents

Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.

Info

Publication number
ES2188743T3
ES2188743T3 ES96907686T ES96907686T ES2188743T3 ES 2188743 T3 ES2188743 T3 ES 2188743T3 ES 96907686 T ES96907686 T ES 96907686T ES 96907686 T ES96907686 T ES 96907686T ES 2188743 T3 ES2188743 T3 ES 2188743T3
Authority
ES
Spain
Prior art keywords
sub
compounds
hydroxy
formula
rent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96907686T
Other languages
English (en)
Inventor
Fumitaka Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2188743T3 publication Critical patent/ES2188743T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

UN COMPUESTO DE FORMULA (I) Y SU SAL FARMACEUTICAMENTE ACEPTABLE, EN EL QUE A ES HIDROGENO, HIDROXI O OY, EN EL QUE Y ES UN GRUPO PROTECTOR DE HIDROXI; AR ES FENILO OPCIONALMENTE SUBSTITUIDO CON UNO O MAS SUBSTITUYENTES SELECCIONADOS DE HALO, HIDROXI, ALQUILO C{SUB,1} }, CF{SUB,3}, ALCOXI C{SUB,1} C{SUB,4} Y CARBOXI O, NAFTILO, BIFENILO, INDANILO, BENZOFURANILO, BENZOTIOFENILO, 1 TETRALONA DILO, FURILO Y TIENILO, ESTANDO ESTOS GRUPOS OPCIONALMENTE SUBSTITUIDOS CON HASTA TRES SUBSTITUYENTES SELECCIONADOS DE ENTRE HALO, ALQUILO C{SUB,1} HIDROXI, NO{SUB,2}, CF{SUB,3} Y SO{SUB,2}CH{SUB,3}; Y R ES HIDROGENO, ALQUILO C{SUB,1} DROXI. ESTOS COMPUESTOS Y LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN SON UTILES COMO AGENTES ANALGESICOS, ANTIINFLAMATORIOS, DIURETICOS, ANESTESICOS O NEUROPROTECTORES, O AGENTES PARA LA APOPLEJIA O PARA EL TRATAMIENTO DE ENFERMEDADES INTESTINALES FUNCIONALES TALES COMO DOLOR ABDOMINAL, PARA EL TRATAMIENTO DE UN SUJETO MAMIFERO, ESPECIALMENTE UN SUJETO HUMANO. ADICIONALMENTE LA PRESENTE INVENCION PROPORCIONA PROCESOS PARA LA PRODUCCION DE LOS COMPUESTOS HIDROXAMICOS DE FORMULA (I) Y SUS COMPUESTOS INTERMEDIARIOS DE FORMULA (II).
ES96907686T 1995-03-31 1996-03-28 Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos. Expired - Lifetime ES2188743T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9500631 1995-03-31

Publications (1)

Publication Number Publication Date
ES2188743T3 true ES2188743T3 (es) 2003-07-01

Family

ID=14125824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96907686T Expired - Lifetime ES2188743T3 (es) 1995-03-31 1996-03-28 Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.

Country Status (35)

Country Link
US (2) US5952369A (es)
EP (1) EP0817772B1 (es)
JP (1) JP3035356B2 (es)
KR (1) KR100258657B1 (es)
AP (1) AP625A (es)
AR (1) AR002729A1 (es)
AT (1) ATE231840T1 (es)
AU (1) AU693336B2 (es)
BG (1) BG62611B1 (es)
BR (1) BR9607750A (es)
CA (1) CA2213815C (es)
CZ (1) CZ306497A3 (es)
DE (1) DE69626009T2 (es)
DK (1) DK0817772T3 (es)
ES (1) ES2188743T3 (es)
HR (1) HRP960141A2 (es)
HU (1) HUP9900767A3 (es)
IL (2) IL117440A0 (es)
IS (1) IS4547A (es)
LV (1) LV11971B (es)
MA (1) MA23832A1 (es)
NO (1) NO974513L (es)
NZ (1) NZ304113A (es)
OA (1) OA10518A (es)
PE (1) PE43397A1 (es)
PL (1) PL322652A1 (es)
RU (1) RU2144917C1 (es)
SI (1) SI9620039A (es)
SK (1) SK129897A3 (es)
TN (1) TNSN96045A1 (es)
TR (1) TR199701082T1 (es)
TW (1) TW408111B (es)
WO (1) WO1996030339A1 (es)
YU (1) YU18696A (es)
ZA (1) ZA962476B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701042A (es) * 1996-02-07 1998-05-31 Pfizer Compuestos del acido hidroxamico.
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
DE69720518T2 (de) * 1996-12-02 2004-02-26 Kyorin Pharmaceutical Co., Ltd. Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
AU732430B2 (en) * 1997-01-10 2001-04-26 Merck & Co., Inc. Efficient synthesis of a chiral mediator
IL130429A0 (en) * 1998-08-24 2000-06-01 Pfizer Prod Inc Process for preparing pyrrolidinyl hydroxamic acid compounds
KR100295740B1 (ko) * 1998-09-17 2001-11-05 박영구 N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
AU2002247886A1 (en) 2001-04-30 2002-11-11 Pfizer Products Inc. Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
GB0821010D0 (en) * 2008-11-17 2008-12-24 Univ Warwick Plant development control composition
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
US9487510B2 (en) 2012-03-05 2016-11-08 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists
GB201210395D0 (en) * 2012-06-11 2012-07-25 Syngenta Participations Ag Crop enhancement compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Also Published As

Publication number Publication date
PE43397A1 (es) 1997-10-13
DE69626009D1 (de) 2003-03-06
BR9607750A (pt) 1998-06-30
EP0817772B1 (en) 2003-01-29
AU5121196A (en) 1996-10-16
NO974513D0 (no) 1997-09-29
WO1996030339A1 (en) 1996-10-03
HUP9900767A3 (en) 2001-01-29
US5952369A (en) 1999-09-14
CA2213815A1 (en) 1996-10-03
BG101896A (en) 1999-01-29
KR19980703476A (ko) 1998-11-05
CZ306497A3 (cs) 1998-07-15
DK0817772T3 (da) 2003-05-19
KR100258657B1 (ko) 2000-07-01
CA2213815C (en) 2001-12-18
TW408111B (en) 2000-10-11
AU693336B2 (en) 1998-06-25
HUP9900767A2 (hu) 1999-07-28
LV11971A (lv) 1998-02-20
IL117440A0 (en) 1996-07-23
US6110947A (en) 2000-08-29
RU2144917C1 (ru) 2000-01-27
SI9620039A (sl) 1998-08-31
TNSN96045A1 (fr) 2005-03-15
AP625A (en) 1997-12-24
IS4547A (is) 1997-08-19
TR199701082T1 (xx) 1998-02-21
MX9707454A (es) 1998-07-31
BG62611B1 (bg) 2000-03-31
MA23832A1 (fr) 1996-10-01
OA10518A (en) 2002-04-22
NZ304113A (en) 1999-01-28
YU18696A (sh) 1999-06-15
JP3035356B2 (ja) 2000-04-24
HRP960141A2 (en) 1997-10-31
EP0817772A1 (en) 1998-01-14
PL322652A1 (en) 1998-02-16
AP9600791A0 (en) 1996-04-30
JPH11501048A (ja) 1999-01-26
AR002729A1 (es) 1998-04-29
ZA962476B (en) 1997-09-29
ATE231840T1 (de) 2003-02-15
NO974513L (no) 1997-09-29
DE69626009T2 (de) 2003-08-14
SK129897A3 (en) 1998-11-04
IL129479A0 (en) 2000-02-29
LV11971B (en) 1998-06-20

Similar Documents

Publication Publication Date Title
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
ES2064310T3 (es) Procedimiento para preparar compuestos de imidazopiridina.
ES2185665T3 (es) Derivados de benzofurano como antagonistas de taquicininas.
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
ATE124047T1 (de) Oxazolopyridinderivate, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen.
AR039673A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ES2194213T3 (es) Beta-carbolinas-4- sustituidas en calidad de inmunomoduladores.
ES2169248T3 (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
UY28343A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
AR009938A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos
AR035502A1 (es) Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
ES2167021T3 (es) Derivados de acido 4-bifenil-4-hidroxibutirico sustituidos como inhibidores de metaloproteasa de matriz.
FI803264L (fi) 2-hydroxialkyl-3,4,5-trihydroxipiperidiner foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
ES2014482B3 (es) Nuevas 2-tiazolil imidazo/1,2-a/pirimidinas y sus sales, su procedimiento de preparacion, su aplicacion a titulo de medicamentos y las composiciones que las encierran.
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR065208A1 (es) Derivados de tetrahidronaftaleno sustituidos con heterociclos o sus analogos bencilsustituidos, metodo de preparacion, medicamentos que los contienen y usos de los mismos, como ligandos de receptores 5-ht7, en patologias asociadas al snc, entre otras.
AR004726A1 (es) Derivados 25-hidroxi-16-eno-26,27-bis homo-colecalciferol, compuestos intermediarios para su preparacion, composiciones farmaceuticas que loscontienen y uso de dichos derivados para fabricar un medicamento.
ES2069719T3 (es) Nuevos derivados de tiofeno, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.